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I 1051 -136 I Effect~~f Pil~i~ainideinCardiover~i~nor
Maintaining Sinus Rhythm for Patients with
Chronic Atrial Fibrillation
K. Okishige, M. Nishizaki, K. Aonuma, K. Azagami, M. Igawa, N. Yamawake.
Kanagawa Arrhythmia TaskForce Investigators, Kanagawa, Japan
Pilsicainide (P), a new antiarrhythmic agent which belongs to class Ic, has
bean introduced to investigate the efficacy of pharmacological cardioversion
of atrial fibrillation (AF) and to maintain normal ainus rhythm (NSR) after
electrical oardioversion (EC) of AF in a randomized, placebo-controlled,
multicanter trial prospectively in 42 patients (pta). We compared the effects
of P and a placatm (PL) in chronic AF in 36 and 6 pts, respectively,average
age 57 (31 - 82), female/male (7/36), with or without organic heart disease,
78 and 22Y0, respectively. All pts received warfarin anticoagulation under
guidelines to maintain a prothrombine time of 1.5 -1.6 times the control,
a month prior to EC. The pts were randomized to receive P or PL. overall,
in 9 out of 36 pta (25%), AF converted to NSR pharmacologically and has
been maintained by P. In 25 (93%) out of 27 pts NSR resumed, and they
were maintained on P therapy. All pts were followed for a maximum period
of up to 2 yeara. 13 out of 34 pts on P (3S%) after successful EC remained
in NSR, whereas, all 6 pts on PL had recurrence of AF,and in 1 pt a massive
cerebral infarction occurred two days after EC. All PL pts failed to maintain
NSR. There waa no statistically significant difference in the mean P level
between those with and without recurrence (0.46 + 0.04 vs 0.44 + 0.09
pg/ml, p = 0.27). Noadverae effects of P were observed during the follow-up
period. Conclusion: P is relatively effective and safe, and well tolerated in
maintaining NSR after cardioveraion of AF.
/ 1051-137] The Effectiveness of Oral Fle~ainidaand
Propafenone in the.Cardioversion and
Prophylaxis of Paroxysmal Atrial Fibrillation
A. Navazio, M.G. Mcdena’, G. Chesi, E. Catellani, P.Montanari. 17eptof
Cardiology Franchini Hospital Montecchio E. (RE), Italy, 1Dept of
Cardiolog~ Univereifyof Modena, Italy
Theaimofthepresent study wastodetermine the efficacyof oral Propafenone
(P) and Flecainide (F) in the cardioveraion of recent paroxysmal atrial fibril-
lation (PAF) which does not resolve spontaneously. 180 pts were included
into the study with PAF of less than 4S hour duration. Exclusion criteria
were atrial fibrillation of more than 2 days; ejection fraction by echocardio-
gram < 400/o;left atrial size (by M-mode) > 55 mm; poor hemodynamic
response to arrhythmia; myocardial. ischemia; acute myocardial infarction.
Patients not excluded were kept in observation for24 hra. We observed that
136 pts (76.7Yo)during this period returned spontaneously to sinus rhythm;
the remaining 42 pts (23.3%) underwent pharmacologic cardioveraion in a
randomized fashion with oral F (19 pts) or P (23 pts). We initiated, in pts
receiving P,a loading dose of 600 mg, 300 mg 6 hrs after and 300 mg every
12 hra for the next 72 hrs, and, in pts receiving F, a leading dose of 200 mg,
100 mg 3 hra after and 100 mg eve!y 12 hra for the next 72 hrs. There were
no significant differences betweenthe twotreatadandthe treatadandnon
treatad groupe forage, gender, left atrial size, associated cardiopathies and
time the arrhythmia occurred.
Results.’Sinus rhythm was restored in 14/19 pts in group F and in ltV23
pts in group P (p= 0.5); the mean time was respectively of 6 * 9.68 hre
in group F and 13.7 & 17.1 in group P (p = 0.37). After cardioversion each
group underwent prophylaxis therapy with the same drug that determined
the interruption of their arrhythmia (P 300 mg BID; F 100 mg BID). All 32 pts
had a follow-up period of 12 months. Three relapses were seen per group
(month 1,7 and 10 in group P and 4,6 and 10 in group F). According to chi
square analysis this difference was not statistically significant (p= 0.8). From
these results we noticed that the efficacy of the two drugs in cardiovefting
PAFof duration of more than 24 hra and preventing new episodes are almost
equivalent. We also would like to point out the fact that in the majority of
pta with lone atrfal fibrillation the spontaneous restoration to sinus rhythm
happenad during the 24-hour observation period.
1051-138 Oral Amiodarone Increases Efficacy of DC
Cardioversion in Patients with Chronic Atrial
Fibrillation and Organic Heart Disease
A. Capucci, D. Aschieri, G.Q. Villani, F. Paaaerfni,F. Groppi, A. Rosi,
S. Amfzzoli. Cardiology Department, Ospadale Civile, Piacenza, Italy
Aim of our study was to assess the effectiveness of oral pretreatment with
amiodarone (Am)on repeatedDC cardiovereions(DCC)in patients (pts)
with chronic atrial fibrillation (AF)andorganichearfdiseaseandto evaluate
the efficacyof the drug to maintainsinus rhythm(SR)at 2 weekfollow-
UP.Method 92 pta were included into the study randomized into 3 groups
comparable for age, sex, underlying heart disease, left atrial size, body
surface area and AF duration time: Group A = 31 pts (Am 400 mglday 1
month before DCC continued at 200 mg/day after DCC); Group B = 30 pts
(Placebo); Group C =31 pts (Sodi-Pallares solution 24 houre before DCC).
After one month of oral anticoagulation (INR 2.5-4), each pt was submitted
to a stepwise DCC (100, 150, 2f20, 360 Joules). Resu/ts: Spontaneous
conversion to SR during Am pretreatment was achieved in 8 pts (25%).
Group.4 GroupB GroupC P
DCC efficacy 88”h 65% 56”A A VSB -=0.05
(“/0pts) A W C ; 0.05
Jouleslm2 112 * 11 119 l 10 103 * 14 C vs A s 0.01
% AF
C va B z 0,01
32”/. 520/. 560/. A VSB s 0,01
recurrence AvaCs 0.01
In conclusion our data demonstrate that oral Am before DCC increases
the number of spontaneous conversion to SR, increases DCC efficacy and
prevents early AF recurrences. Sodi-Pallares infusion favorably interferes
with atrial defibrillation threshold.
/ 1051 -139 I ProPafenoneasaSingle Oral Loading Dossvs
Placebo in Recent Onaet Atrial Fibrillation: la it
Safe?
A. Capuooi1,G. Boriani2, M. Biffi 2, 1.Rubino2, G.Q. Villani 1, D. Aschien i.
4Cardiology Department, Ospedale Civile, Piacenza, lfal~ 2 Institute of
Cardiovascular Disease, UniversifyofBologna, Italy
In 416 pts with raoent onset atrfal fibrillation (AF) (< 72 hours duration)
we evaluated safety and efficacy of oral propafenone (PF) vs placebo on
sinus rhythm (SR) restoration. All the pts were in NYHA class s 2 and were
hospitalised. The pts were randomly allocated to treatment with oral ba.ding
dose with PF 600 mg as single dose (255 pts) or placebo (161 pts). All pts
were submitted to Helter monitoring and conversions to SR were evaluated
at 3 and 8 h togather with collateral or proarrhyfhmic effects. Resu/ts:
PF(255 pte) Placebo (161 pta) pvalue
SR s 3 h 123 (480/.) 33 (20%)
SR s 6 h
0.01
201 (790A) 54 (33%) 0.01
Conversiontime(h) 4.2 + 3.7 7,9 + 8.2 0.01
Adverse eftecfs 9 (3,5%) 3 (1,8%) 0.05
Atrial flutter 20 (8%) 11 (6.8%) n.s.
The PFadveraeeffacts were: slight hypotension in5 pte,junctional rhythm
in 1 pt and QRS enlargement >0.12 see in 3 pts. The only one episode of
atrial flutter with 1:1 conduction was in the placebo group (240 baat/min).
The other episodes of atrial flutter had a 2:1 and 3:1 atrio-ventricular block.
Pauses >2 sac were recorded in 3 pta on PF and in 4 pta on placebo. In
conclusion PF at 600 mg single loading oral dose is safe when the pta are
at rest. The adverse events are minor. Atrial flutter is a mmmon arrhythmia
before SR restoration in these pts with recent onset AF. PF did not increase
the likelihood of 1:1 conduction. The efficacy of oral PF to restore SR is
confirmed.
I 1051-1401 Recant-Onset Atrial Fibrillation:
Placebo-Controlled Evaluation of tha Efficacy of
Propafenone in Elderly Subjacts
G. Boriani, A. Capucci, M. Biffi, G. Botto, 1.Rubino, S. Della Casa,
T. Broffoni, M. Sanguinetti, B. Magnani. hrstitute of Cardio/og~ University of
Bobgna, /ta/y Atria/ Fifvf//atiorr/ta/iarrStudy Group, /ta/y
The efficacy and safety of propafenone (PFN) as single oral loading dose in
converting recent-onset AF (S 7 days duration) to sinus rhythm (SR) within 3
and 8 hours were evaluated in a single-blind, placebo-mntrollsd study. After
2 hours of clinical observation, 240 hospitalised patients (pts), NYHA class
s 2, without signs of heart failure were randomly allocated to treatment with
PFN (600 mg as single oral dose) or placetxr (PIA) during Helter monitoring.
Data were analysad acmrding to pts age: s 60 yeara (55 pts treated with
PFN and 59 pts treated with PLA) and >60 yeare (64 pts treatad with PFN
and 62 pts treated with PLA).Resu/ts:
Pta ageds 60 years Pts aged> 60 ysars
PFN (n = 55) PM (n =59) PFN (n = 64) PLA (n = 62)
SR s 3 hrs 31 (560/.) 15 (250/.)” 25 (39%) 7 (11”/0)””
SR s 8 hce 44 (800/o) 27 (46”A)** 47 (73%) 18 (29)**
Legend: p <0.005 and .“ p <0.001 versus PFN.
Mean conversion time to SR didn’t differ among the 4 eubgroupa. The
ooourenoaof significant adveme effects (phases of sustained atrial flutter or
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tachycardia, sinus pauses > 2s, QRS enlargement > 0.12s, hypotension)
didn’tdifferamong patients ageds 600r> 60 yeare, either inptstreated with
PFN (16% and 14% reepactively) or PLA (89’.and 8% respectively). in con-
clusion, the high efficacy of PFN as single oral loading dose in recent-onset
AF without aigns of heari failure is confirmed even in elderly subjects, with a
favorable safety profile. Moreover, conversion to SR after PLA appears to
ooourr leas frequently in elderly patients.
n1052 Pharmacologic Modulation of
Vascular-Endothelial Function
Wednesday,March 19, 1997, 9:00 a.m.–n :00 a.m.
AnaheimConventionCenter,Hall E
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m1052132 AcuteHemodynamicandRenalEffectsoftheEndothelin-1ReceptorAntagonistTAK-044in
PatientaWithoutHeartFailure
G. Siitaoh, M. Fleisch, X.-W. Yan, R. Wenzel, C. Binggeli, M.C. Bianchetti,
W. Kiowski, T. LOscher.Cardiology Units, University Hospitals of Bem and
ZOffch,Switzedand
Endothelin-1 participates in the regulationof arteriolarand venoustone in
patients (pts) with markedly impaired left ventricular (LV) function and con-
gestive hearf failure (CHF). However, its role in the regulation of vascular
tone in the absence of CHF in not eatabltshed. Accordingly, we tested the
acute effects of single dose, randomized administration of TAK-044 (25, 50
or 100 mg), an endothelin-1 type A and B reoeptor antagonist, or matching
placebo given over 15 minutes intravenously on cardiac and renal hemo-
dynamioe in 24 pte (56 + 6 yeare, 5 females, 19 males) with LV ejection
fraction z 40% and no CHF. Regular medication was discontinued the day
before the study. Renal (pare-aminohippuric acid and inulin clearance) and
cardiac hemodynamice (pulmonary and radial artery catheters, and ECG,
respectively) were determined before and during 4 hours after infusion. Be-
cause there was no clear dose-response relationship, all TAK-044 pts (n =
17)were treated as a group and compared to placebo (n = 7). TAK-044 re-
duced mean arterial (7.6 mmHg), pulmonaty (4 mmHg) aswell as pulmonary
capillary wedged pressures (1.5 mmHg [differences of all measurements vs.
placebo; p < 0.01]). Cardiac index increased (0.25 mUmin/BSA) and hearf
rate and right atrial pressure were,unchanged. Systemic vascular resistance
fell (114dynes.seo.cm-5). Renal plasma flow increased non-significantly and
glomerularfiltration rate was unchanged by TAK-044. Accordingly, renal vas-
cular reSiStSnOSfell (mean 14.1%, p -=0.05) and this change was similar to
that of systemic vascular resistance (mean 22.6%, p < 0.01). Thus, in pts
with no symptoms of CHF, endothelin-1 also contributes to atteriolar tone
and systemic receptor blockade leads to va$cdilation and improves cardiac
index. The lack of influence on right atrial pressure suggests no major effects
on venous tone. Finally, the renal circulation in these pts is not particularly
sensitive to the effects of blockade.
m1052133 N-acetylcysteineImprovesCoronaryVascularEndothelialDysfunction
N.P.Andrews, S. Husain, A. Prasad, M. Husain, R. Mincemoyer,
J.A. Panza, R.O. Cannon, Ill, A.A. Quyyumi. MY, Bethesda, MD, USA
Reduced endothelial nitricoxide(NO) availability in patients (pts)with atheroscle-
rcals may be due to increased breakdown of NO by oxygen free radioala.
Redueed thiola such as N-acetyloysteine (NAC) may improve the bkxwail-
ability of NO by their antioxidant effects or by forming stable adducts of NO.
To investigate whether coronary vascular endothelial dysfunction can be im-
proved byNAC, westudiedtheeffactof intrecoronary NAC(46 mglmin) on the
respcnsea to aoetyloholine (ACh, 30 Kgfmin), sodium nitroprueeide (SNP),
ahd adenoaine in 17 pts with normal Coronav arteries ormildatheroeolerosis
of epicardial mronary arteries. Diameter (D mm) was measured by quantita-
tive angicgraphy, and coronav vascular resistance (R) was estimated using
Doppler flow veicoity.
ACh SNP Adenosine
“/4JR D “%$R D “/6JR D
Control –33 1,9 –8 2.4 -75 2.5
NAC –48 2.1 -42 2.5 -74 2.5
PValue 0.003 0.002 0.006 0.001 0,8 0.8
Intraoorcnary NAC infusion had no effect on resting hemodynamice, but
improved microveacular and epicardial vaacdilation in response to ACh and
SNP, but not to adenosine. The effect of NAC was more pronounced in
pts with depressed response to ACh. Thus, NAC specifically enhances the
effects of endogenous (stimulated by ACh) and exogenous NO (SNP) on the
coronaV vascuiature and may have potential therapeutic value in pts with
endothelial dysfunction.
-~ V.SOdi,atOr~ffeCtS Of f3rSiflNatri.retic Peptide
inCoronaryConductanceandResistance
Arteries
C. Zellner, K. Sudhir, A.A. Protter, E. Ko, S.J. Hutchison, T.-M. Lee,
M.R. Pothireddy,TM. Chou, K. Chatterjee, Univeraityof Ca/ifomia, San
Francism, CA, USA
Brain natriuretic peptide (BNP) is a hormone secreted predominantly by ven-
tricularmyocytes in heart failure, presumably asacompensato~ vascdilatory
mechanism. It has been shown to ameliorate symptoms and EKG abnor-
malities in patients with coronay spasm. BNP-induced vasodilation in vitro
is mediated via increased cGMP, We examined the coronary vaaodilatory
effects of BNP in vivo in 20 anesthetized pigs. Epicardial corona~ cross-
seotionai area (CSA) was measured by intracoronaty ultrasound; average
coronary peak flow velocity (APV) was simultaneously measured by Doppler
velocimet~; and volumetric coronary blood flow (CBF) was calculated. In 14
pigs, intrecoronary BNP (1 pMto O.1KM) induced significant dose-dependent
increases in CSA (12 +3% at 0.1 vM), APV (5 & 4%) and CBF (14+ 6%),
similar in magnitude to intracoronary nitroglycerin 10 vM. The vasodilator re-
sponse was accentuated when the coronary vasculature was preconstrieted
with either endothelin-1 10 nM (increase in CBF: 27 + 6%) or acetylcholine
10 nM. Pre-treatment with the nitric oxide synthase inhibitor nitro-L-arginine
methylester (100 uM) did not inhibit BNP induced vasodilation in epicardial
arteries, but significantly attenuated BNP-induced increase in CBF from 14
* 6% to –3 + S’XO.in another group of pigs (n = 6), pre-treatment with the
cyclooxygenaae inhibitor indomethacin (2 mgkg IV) induced transient eleva-
tions in blood pressure, and significantly attenuated BNP-induced increase
in CSA from 10 + 3Y0to –2 + 3%, We conclude that BNP is a potent epi-
cardia coronary vascdilator, especially in preccnstricted atieries, with less
effects on coronary resistance arteries. This effect may explain BNP-induced
amelioration of coronaty vasospasm. BNP-induced epicardial coronary va-
scdilation may partially be mediated via release of prostaglandins that have
been suggested to influence cGMP in smooth muscle.
[1052-149 I TheEffectofSumatriptanontheHuman
CoronaryCirculation
J. Saucedo-Matar, D.M. Bondie, D.W.M. Muller, SW. Werns. University of
Michigan, Ann Arboc Ml, USA
Previous studies have shown that serotonin is released in the coronary circu-
lation in patients with unstable angina and during PTCA. There areoonflicting
data regarding serotonin receptors in human coronary arteries. Both constric-
tion and dilation of coronary arteries have been observed after stimulation
of 5-hydroxytryptamine (5HT) receptors. This study examined the effect of
a selective 5HTI receptor agonist, sumatriptan, on the corona~ circulation
of 6 patients. Coronaty artery diameter (Diameter) and blood flow (CBF)
were measured after intracoronary acetylcholine (ACh), adenosine (ADO),
and nitroglycerin (NTG), and after intravenous sumatriptan 0.1 mg/min x
30 min. Diameter was measured by computerized quantitative angiography.
CBFwascalculated fmm Diameter andcoronaty flow velocity measured with
a Doppler guidewire.
ACh ADO NTG Sumatriptsn
Diameter +16 +4% +32 &8% +26+ 12% –7 & 60/0
CBF +40l21% +-378& 1160/0 +66 * 377. –17* 7*A
X + SEM exprsssed as percentchange from baseline
Diameter increased after both ACh, an endothelium-dependent vascdila-
tor, and NTG, an endothelium-independent veecdilator. CBF increased after
ACh, ADO, and NTG. Neither Diameter nor CBF increased during suma-
triptan infusion. Thus, intravenous sumatriptan did not dilate epicardial or
resistance coronary arteries despite evidence of preserved endothelium-
dependent and endothelium-independent vasodilation. The results suggest
that 5HTI receptorsare notan important mechanism of ooronaryvasodilation
in the human heart.
11052-150/ fiypOXemia Stimulates ReleaS50f IEndothelin I in
Obstructive Sleep Apnoea Syndrome
M.R. Schulze, F.Schmidt, H. Zhang, J. Niedermeyer, W.G. Daniel.
Depeflment of Cardiolog~ University Clinic Dresden, Germany
Endothelin I (ET 1)and Angiotensin II (AT H)are strong known vascconstric-
